GLP-1 receptor agonists and breast cancer risk in type 2 diabetes.

Guo Cheng et al. . JCO 43, 10557-10557(2025).

May 28, 2025

DOI: 10.1200/JCO.2025.43.16_suppl.10557 (https://doi.org/10.1200/JCO.2025.43.16_suppl.10557)

Conclusions:

GLP-1RAs was associated with an increased incidence of breast cancer compared to other antidiabetic regimens in patients with T2DM in a long-term observation. Acting on identical pathway, GLP-1RAs may show a blunt effect versus DPP4i in obese patients. The study is empowered by an enormous sample size in Epic Cosmos. Future improvements include stratifying exposure levels and stringently matching confounders.

Thyroid Cancer Risk with GLP-1 Receptor Agonists: Evidence, Knowledge Gaps, and the Path Forward

David Toro-Tobon et al in Thyroid® (2025.01)

DOI: 10.1089/thy.2024.0690 (https://doi.org/10.1089/thy.2024.0690)

GLP-1 Receptor Agonists and Suicidality-Caution Is Needed.

Salvo F, Faillie JL. JAMA Netw Open. 2024 Aug 1;7(8):e2423335. PMID: 39163050.

August 20, 2024

DOI: 10.1001/jamanetworkopen.2024.23335 (https://doi.org/10.1001/jamanetworkopen.2024.23335)

https://link.springer.com/article/10.1007/s43440-024-00629-x#citeas

https://www.health.harvard.edu/staying-healthy/glp-1-diabetes-and-weight-loss-drug-side-effects-ozempic-face-and-more